Login / Signup

DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Natália Souza Freitas QueirozRogério Saad HossneRenata de Sá Brito FrÓesFrancisco Guilherme Cancela E PennaStefania Burjack GabrielAdalberta Lima MartinsFábio Vieira Teixeira
Published in: Arquivos de gastroenterologia (2021)
Discontinuation rates following a switch to a biosimilar in patients with IBD increase over time. However, it was not possible to confirm the nocebo effect as a reason for discontinuation. Therefore, long-term studies evaluating the use of biosimilars to monitor adverse events and potential nocebo effects in post-marketing surveillance are still needed.
Keyphrases
  • patients with inflammatory bowel disease
  • rheumatoid arthritis
  • public health
  • risk assessment
  • human health